Compare Summit Therapeutics Inc (SMMT) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Teladoc Health Inc — how do they compare? Summit Therapeutics Inc trades at $17.55 (market cap $13.79B), while Teladoc Health Inc trades at $6.1 (market cap $1.14B). The key difference: Summit Therapeutics Inc is far larger — about 12.1× Teladoc Health Inc's market cap. Which is the better fit depends on your goals.
| SMMT | TDOC | |
|---|---|---|
Market Cap | $13.79B | $1.14B |
Sector | Health | Health |
52-Week High | $26.38 | $9.72 |
52-Week Low | $12.43 | $4.47 |
Enterprise Value | $13.11B | $1.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
TDOC trades at $6.26, down 0.32% on the day, with a bearish technical signal and neutral oscillators. The company reported a net loss of $200.32 million in 2025, though revenue remains stable at $2.53 billion. Recent news includes the appointment of a new CFO and ongoing legal investigations, while analyst consensus is a $8.88 price target with a hold-heavy rating.
The outlook is mixed: valuation metrics like P/S of 0.45 and EV/EBITDA of 6.5 suggest potential undervaluation, but persistent losses and negative cash flow in 2025 pose risks. Upside hinges on profitability improvements from its integrated care segment, while competitive pressures and weak BetterHelp performance are headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
